OpGen Group Company Ares Genetics Nominated for Austrian Innovation Award for AI-powered Molecular Antibiotic Susceptibility ...
September 08 2020 - 7:30AM
OpGen, Inc. (Nasdaq: OPGN, “OpGen”), announced today that its
subsidiary Ares Genetics GmbH (Vienna, Austria; “Ares Genetics”)
has been nominated for the 40th Austrian Innovation Award (Ref. 1).
Ares Genetics has been selected by an expert
jury as one of six finalists for its artificial intelligence (AI)
powered, next-generation sequencing (NGS) based molecular
antibiotic susceptibility test (AST) marketed under the brand name
ARESupa – Universal Pathogenome Assay. The Austrian Innovation
Award is awarded by the Federal Ministry for Digital and Economic
Affairs and represents Austria’s most distinguished award for
innovative companies.
In a press release announcing the nominees (Ref.
1), Federal Minister for Digital and Economic Affairs Margarete
Schramböck was quoted, “For the 40th time, the Ministry of Digital
and Economic Affairs awards the Austrian Innovation Award for
outstanding innovations and top achievements. Particularly in
current times, innovation plays a very important role: The
[nominated] companies strengthen the competitiveness of [Austria as
a] business hub and thereby sustainably secure jobs. Moreover,
innovative projects are of particular importance to jointly emerge
stronger from the current [Covid-19]
crisis.”
Information on antibiotic susceptibility of
pathogens is of utmost importance for clinical practice,
epidemiology and public health purposes as well as for the
development of pharmaceutical products in the infectious disease
sector. Ares Genetics has therefore developed the ARESupa –
Universal Pathogenome Assay, which is capable of accurately
predicting antibiotic susceptibility via AI-powered interpretation
of high-throughput DNA sequencing data as demonstrated in a recent
multi-center US study (Ref. 2). The ARESupa is based on
whole-genome sequencing of bacterial strains isolated from clinical
specimens, combined with data analysis and interpretation powered
by ARESdb, Ares Genetics’ unique, proprietary reference database on
genetic antimicrobial resistance markers. ARESdb covers genomes of
more than 55,000 bacterial strains and associated susceptibility
data for more than 100 different antibiotics.
The ARESupa had already been recognized with the
MERCUR Innovation Award in the category Life Sciences 2019 (Ref. 3)
and is currently offered by Ares Genetics for non-diagnostic
applications in epidemiology, infection control, and outbreak
analysis for customers in the public health sector and the
pharmaceutical industry through the Company’s AI-powered
bioinformatics platform www.ares-genetics.cloud.
References
-
https://www.ots.at/presseaussendung/OTS_20200903_OTS0052/schramboeck-sechs-unternehmen-fuer-staatspreis-innovation-2020-nominiertPlease
refer to the original press release for the original statement by
the Federal Minister for Digital and Economic Affairs Margarete
Schramböck in German. The statement included here represents an
unauthorized convenience translation.
- Species Identification and Antibiotic Resistance Prediction by
Analysis of Whole Genome Sequence Data Using ARESdb - An Analysis
of Isolates from the Unyvero Lower Respiratory Tract Infection
Trial. Ines Ferreira, Stephan Beisken, Lukas Lueftinger, Thomas
Weinmaier, Matthias Klein, Johannes Bacher, Robin Patel, Arndt von
Haeseler and Andreas E. Posch. 2020. Journal of Clinical
Microbiology 58(7): e00273-20.
-
https://news.wko.at/news/wien/MERCUR-Innovationspreis:-Wirtschaftskammer-Wien-zeichnet-in.html
About OpGen, Inc.
OpGen, Inc. (Gaithersburg, MD, USA) is a
precision medicine company harnessing the power of molecular
diagnostics and bioinformatics to help combat infectious disease.
Along with subsidiaries, Curetis GmbH and Ares Genetics GmbH, we
are developing and commercializing molecular microbiology solutions
helping to guide clinicians with more rapid and actionable
information about life threatening infections to improve patient
outcomes, and decrease the spread of infections caused by
multidrug-resistant microorganisms, or MDROs. OpGen’s product
portfolio includes Unyvero, Acuitas AMR Gene Panel and Acuitas®
Lighthouse, and the ARES Technology Platform including ARESdb,
using NGS technology and AI-powered bioinformatics solutions for
antibiotic response prediction.
For more information, please visit
www.opgen.com.
Forward-Looking Statements by
OpGen
This press release includes statements regarding
the nomination of OpGen’s subsidiary Ares Genetics GmbH for the
Austrian national innovation award and Ares Genetics’ molecular
antibiotic susceptibility test, ARESupa. These statements and
other statements regarding OpGen’s future plans and goals
constitute "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the
Securities Exchange Act of 1934 and are intended to qualify for the
safe harbor from liability established by the Private Securities
Litigation Reform Act of 1995. Such statements are subject to risks
and uncertainties that are often difficult to predict, are beyond
our control, and which may cause results to differ materially from
expectations. Factors that could cause our results to differ
materially from those described include, but are not limited to,
our ability to successfully, timely and cost-effectively develop,
seek and obtain regulatory clearance for and commercialize our
product and services offerings, the rate of adoption of our
products and services by hospitals and other healthcare providers,
the realization of expected benefits of our business combination
transaction with Curetis GmbH, the success of our commercialization
efforts, the impact of COVID-19 on the Company’s operations,
financial results, and commercialization efforts as well as on
capital markets and general economic conditions, the effect on our
business of existing and new regulatory requirements, and other
economic and competitive factors. For a discussion of the most
significant risks and uncertainties associated with OpGen's
business, please review our filings with the Securities and
Exchange Commission. You are cautioned not to place undue reliance
on these forward-looking statements, which are based on our
expectations as of the date of this press release and speak only as
of the date of this press release. We undertake no obligation to
publicly update or revise any forward-looking statement, whether as
a result of new information, future events or otherwise.
OpGen Contact: Oliver Schacht
CEOInvestorRelations@opgen.com
Press Contact: Matthew Bretzius FischTank
Marketing and PR matt@fischtankpr.com
Investor Contact: Megan Paul Edison Group
mpaul@edisongroup.com
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jun 2024 to Jul 2024
OpGen (NASDAQ:OPGN)
Historical Stock Chart
From Jul 2023 to Jul 2024